drugset / Trial / NCT02750150

Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients

NCT02750150

Phase 3 Completed 42 enrolled University Hospital, Lille
RandomizedParallel-groupOpen-labelTreatment

Summary

Knowledge and management of bleeding in severe trauma has changed. A specific coagulopathy is present in 40% of cases. It has a very early onset and this coagulopathy is associated with increased mortality. It must be detected and treated early, as illustrated by the military medical data, from the Iraq war and civilian medicine. However, fresh frozen plasma (FFP) requires a thawing step.The French army has encouraged the development of a freeze-dried plasma of innovative because viral inactivation and universal blood grouping, well tolerated, with a reduced risk of TRALI. This sophisticated therapeutic product can be administered after 6 minutes of reconstitution without the need for cross-matching. Nevertheless, its used is currently reserved for military purpose in overseas operations and needs to be evaluated for civil use. To this end, the investigators need to evaluate the impact on coagulopathy of an immediate availability of plasma.

Timeline

Start
2013-07-09
Primary completion
2016-04-17
Completion
2016-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Freezed-dried plasma Unknown 4 unknown
Comparator Fresh Frozen Plasma Protein / enzyme biologic 4 unknown